Title:
FUSION PROTEINS TARGETING CD3 AND CD47
Document Type and Number:
WIPO Patent Application WO/2023/072217
Kind Code:
A1
Abstract:
Bispecific fusion proteins targeting CD3 and CD47 are provided. In particular, the fusion protein targeting to CD3 and CD47 comprises an anti-CD3 antibody module and an N-terminal IgV-like domain of human SIRPα that blocks CD47 activity. The bispecific fusion proteins targeting CD3 and CD47 recruit T cells to the CD47 positive cancer cells. The design of the bispecific fusion proteins targeting CD3 and CD47 show strong antigen binding and high T cell activation.
Inventors:
SUN ZHE (CN)
Application Number:
PCT/CN2022/128081
Publication Date:
May 04, 2023
Filing Date:
October 27, 2022
Export Citation:
Assignee:
GUANGZHOU LINTONPHARM CO LTD (CN)
International Classes:
C07K16/46; A61K39/39
Domestic Patent References:
| WO2016024021A1 | 2016-02-18 | |||
| WO2013115926A2 | 2013-08-08 | |||
| WO2016116626A1 | 2016-07-28 |
Foreign References:
| US20200157223A1 | 2020-05-21 | |||
| US20200095339A1 | 2020-03-26 | |||
| CN112533954A | 2021-03-19 | |||
| US20190352419A1 | 2019-11-21 |
Attorney, Agent or Firm:
SHANGHAI DIANSHI PARTNERS, P.C. (CN)
Download PDF: